Teriparatide
- Generic Name
- Teriparatide
- Brand Names
- Forsteo, Forteo, Movymia, Kauliv, Sondelbay, Teriparatide Sun, Terrosa, Livogiva
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 52232-67-4
- Unique Ingredient Identifier
- 10T9CSU89I
- Background
Teriparatide is a recombinant parathyroid hormone (PTH) analog and a potent osteoanabolic agent. It is made up of the first amino(N)-terminal 34 amino acids of the human PTH. First approved in the United States in November 2002 and in Europe in April 2003, teriparatide makes the first approved drug in a new category of osteoporosis therapy called anabolic th...
- Indication
Teriparatide is indicated:
- Associated Conditions
- Osteoporosis, Osteoporosis caused by Glucocorticoid Treatment, Primary Osteoporosis
- Associated Therapies
- -
Combined Anabolic Therapy
- Conditions
- Interventions
- First Posted Date
- 2024-08-16
- Last Posted Date
- 2024-10-18
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 50
- Registration Number
- NCT06558188
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
Precision Medicine Approach for Osteoporosis - Follow Up Study
- First Posted Date
- 2024-02-20
- Last Posted Date
- 2024-02-20
- Lead Sponsor
- Hartmut Malluche, MD
- Target Recruit Count
- 40
- Registration Number
- NCT06264609
- Locations
- 🇺🇸
University of Kentucky, Lexington, Kentucky, United States
Sequential Therapies After Osteoanabolic Treatment
- Conditions
- Interventions
- First Posted Date
- 2023-12-11
- Last Posted Date
- 2023-12-15
- Lead Sponsor
- 424 General Military Hospital
- Target Recruit Count
- 150
- Registration Number
- NCT06164795
- Locations
- 🇩🇪
Department of Medicine III and Center for Healthy Aging, Technische Universität Dresden, Dresden, Germany
🇬🇷251 Airforce & VA General Hospital, Athens, Greece
🇬🇷424 General Military Hospital, Thessaloniki, Greece
Teriparatide on Maxillary Sinus Floor Osseointegration
- Conditions
- Interventions
- First Posted Date
- 2023-09-29
- Last Posted Date
- 2023-11-30
- Lead Sponsor
- Universidad de Valparaiso
- Target Recruit Count
- 42
- Registration Number
- NCT06061354
- Locations
- 🇨🇱
Facultad de Odontología, Universidad de Valparaiso, Valparaíso, Valparaiso, Chile
Study of the Key Techniques of Prevention and Treatment of Osteoporotic Refracture
- Conditions
- Interventions
- First Posted Date
- 2023-05-19
- Last Posted Date
- 2024-10-24
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 2478
- Registration Number
- NCT05866029
- Locations
- 🇨🇳
Beijing Friendship Hospital, Capital Medical University, Beijing, China
🇨🇳Beijing Hospital, Beijing, China
🇨🇳Beijing Pinggu Hospital, Beijing, China
Study Evaluating PK of PTH Administered Orally Via RaniPill™ Capsule
- Conditions
- Interventions
- First Posted Date
- 2021-12-20
- Last Posted Date
- 2022-10-31
- Lead Sponsor
- RANI Therapeutics
- Target Recruit Count
- 50
- Registration Number
- NCT05164614
- Locations
- 🇦🇺
Nucleus Network, Melbourne, Australia
Novel Precision Medicine Approach to Treatment of Osteoporosis Based on Bone Turnover
- First Posted Date
- 2021-12-09
- Last Posted Date
- 2024-07-05
- Lead Sponsor
- Hartmut Malluche, MD
- Target Recruit Count
- 60
- Registration Number
- NCT05151484
- Locations
- 🇺🇸
University of Kentucky, Lexington, Kentucky, United States
Efficacy of WJ-derived Mesenchymal Stem Cells in Combination With Parathyroid Hormone for Vertebral Compression Fracture
- Conditions
- Interventions
- First Posted Date
- 2021-08-24
- Last Posted Date
- 2021-08-24
- Lead Sponsor
- Inbo Han
- Target Recruit Count
- 30
- Registration Number
- NCT05018637
- Locations
- 🇰🇷
CHA University, CHA Bundang Medical Center, Seongnam-si, Gyeonggi-do, Korea, Republic of
Real-world Effectiveness and Cardiovascular Safety Study of Abaloparatide in Postmenopausal Women
- First Posted Date
- 2021-07-23
- Last Posted Date
- 2024-04-19
- Lead Sponsor
- Radius Health, Inc.
- Target Recruit Count
- 22054
- Registration Number
- NCT04974723
- Locations
- 🇺🇸
Radius Health, Boston, Massachusetts, United States
Pharmacokinetic and PHarmacodynamic Analysis and Evaluation of Teriparatide (PTH 1-34) Between Sexes
- First Posted Date
- 2021-06-10
- Last Posted Date
- 2021-08-12
- Target Recruit Count
- 30
- Registration Number
- NCT04921124
- Locations
- 🇬🇧
Norfolk and Norwich University Hospitals Foundation Trust, Norwich, Norfolk, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.